Product
LIBP-Rec-Vaccine
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate Efficacy, Safety and Immunogenicity of LIBP Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and BIBP Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) in Healthy Population Aged 18 and AboveStatus: Recruiting, Estimated PCD: 2023-10-01